G Ploussard

Summary

Publications

  1. doi request reprint Urine biomarkers in prostate cancer
    Guillaume Ploussard
    INSERM U955 Eq07, Department of Urology, APHP, CHU Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94000 Creteil, France
    Nat Rev Urol 7:101-9. 2010
  2. doi request reprint Challenging treatment decision-making in older urologic cancer patients
    Guillaume Ploussard
    Department of Urology, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Paris 7 University, Paris, France
    World J Urol 32:299-308. 2014
  3. doi request reprint Comparisons of the perioperative, functional, and oncologic outcomes after robot-assisted versus pure extraperitoneal laparoscopic radical prostatectomy
    Guillaume Ploussard
    Department of Urology, Hospital Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France Electronic address
    Eur Urol 65:610-9. 2014
  4. doi request reprint Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature
    Guillaume Ploussard
    Department of Urology, Saint Louis Hospital, APHP, Paris, France Department of Urology, Jewish General Hospital and Montreal General Hospital, McGill University, Montreal, Canada INSERM 955, Team 7, University Paris 12, Creteil, France Electronic address
    Eur Urol 65:7-16. 2014
  5. doi request reprint Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance
    Guillaume Ploussard
    INSERM U955 Eq07 Departments of Urology and Pathology, APHP, CHU Henri Mondor, Creteil, France Electronic address
    Urol Oncol 31:1060-6. 2013
  6. doi request reprint Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy
    Guillaume Ploussard
    Inserm U955 équipe 7, Departments of Urology and Pathology, CHU Henri Mondor, APHP, Creteil, France Electronic address
    Eur Urol 65:154-61. 2014
  7. doi request reprint Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial
    Guillaume Ploussard
    Departments of Urology and Pathology, Assistance Publique Hopitaux de Paris, CHU Henri Mondor, Creteil, France
    BJU Int 111:988-96. 2013
  8. doi request reprint Extraperitoneal robot-assisted laparoscopic radical prostatectomy: a single-center experience beyond the learning curve
    Guillaume Ploussard
    Department of Urology, Hospital Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94010, Creteil, France
    World J Urol 31:447-53. 2013
  9. ncbi request reprint [Prostate cancer: interpretation of management guidelines]
    Guillaume Ploussard
    Service d Urologie, Hopital Saint Louis, AP HP, 75010 Paris, France
    Rev Prat 63:515-20. 2013
  10. ncbi request reprint [Active surveillance for low-risk prostate cancer]
    Guillaume Ploussard
    Service d Urologie, Hopital Saint Louis, AP HP, Universite Paris 7, Paris, France
    Rev Prat 63:485-8. 2013

Detail Information

Publications38

  1. doi request reprint Urine biomarkers in prostate cancer
    Guillaume Ploussard
    INSERM U955 Eq07, Department of Urology, APHP, CHU Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94000 Creteil, France
    Nat Rev Urol 7:101-9. 2010
    ..In addition, an unmet need remains for markers that differentiate indolent from aggressive cancers, to better inform treatment decisions...
  2. doi request reprint Challenging treatment decision-making in older urologic cancer patients
    Guillaume Ploussard
    Department of Urology, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Paris 7 University, Paris, France
    World J Urol 32:299-308. 2014
    ..Thus, the management of cancer in the elderly is a major public health concern in most Western countries...
  3. doi request reprint Comparisons of the perioperative, functional, and oncologic outcomes after robot-assisted versus pure extraperitoneal laparoscopic radical prostatectomy
    Guillaume Ploussard
    Department of Urology, Hospital Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France Electronic address
    Eur Urol 65:610-9. 2014
    ..In spite of the increasing use of robot-assisted radical prostatectomy (RALP) worldwide, no level 1 evidence-based benefit favouring RALP versus pure laparoscopic approaches has been demonstrated in extraperitoneal laparoscopic procedures...
  4. doi request reprint Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature
    Guillaume Ploussard
    Department of Urology, Saint Louis Hospital, APHP, Paris, France Department of Urology, Jewish General Hospital and Montreal General Hospital, McGill University, Montreal, Canada INSERM 955, Team 7, University Paris 12, Creteil, France Electronic address
    Eur Urol 65:7-16. 2014
    ..This is likely the result of prostate cancer stage migration in the prostate-specific antigen-screening era, and the introduction of minimally invasive approaches such as robot-assisted radical prostatectomy (RARP)...
  5. doi request reprint Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance
    Guillaume Ploussard
    INSERM U955 Eq07 Departments of Urology and Pathology, APHP, CHU Henri Mondor, Creteil, France Electronic address
    Urol Oncol 31:1060-6. 2013
    ..To evaluate the impact of detailed biopsy characteristics such as positive cores location or multifocality on the risk of initial reclassification in prostate cancer (CaP) patients eligible for active surveillance (AS)...
  6. doi request reprint Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy
    Guillaume Ploussard
    Inserm U955 équipe 7, Departments of Urology and Pathology, CHU Henri Mondor, APHP, Creteil, France Electronic address
    Eur Urol 65:154-61. 2014
    ..The debate on the optimal number of prostate biopsy core samples that should be taken as an initial strategy is open...
  7. doi request reprint Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial
    Guillaume Ploussard
    Departments of Urology and Pathology, Assistance Publique Hopitaux de Paris, CHU Henri Mondor, Creteil, France
    BJU Int 111:988-96. 2013
    ..Predictive markers of such a risk are undefined. In addition to PSA and PSAD, low prostate volume and %fPSA are interesting time-varying risk factors and are relevant in biopsy decision-making...
  8. doi request reprint Extraperitoneal robot-assisted laparoscopic radical prostatectomy: a single-center experience beyond the learning curve
    Guillaume Ploussard
    Department of Urology, Hospital Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94010, Creteil, France
    World J Urol 31:447-53. 2013
    ..To report our surgical technique and outcomes after extraperitoneal robot-assisted laparoscopic radical prostatectomy (RALRP)...
  9. ncbi request reprint [Prostate cancer: interpretation of management guidelines]
    Guillaume Ploussard
    Service d Urologie, Hopital Saint Louis, AP HP, 75010 Paris, France
    Rev Prat 63:515-20. 2013
    ....
  10. ncbi request reprint [Active surveillance for low-risk prostate cancer]
    Guillaume Ploussard
    Service d Urologie, Hopital Saint Louis, AP HP, Universite Paris 7, Paris, France
    Rev Prat 63:485-8. 2013
    ..Moreover, due to the slow time evolution of these low-risk cancers, a long-term confirmation of oncological results seems necessary...
  11. doi request reprint Triptorelin in the management of prostate cancer
    Guillaume Ploussard
    Department of Urology and Paris 7 University, APHP, Saint Louis Hospital, Paris, France
    Future Oncol 9:93-102. 2013
    ..The new formulation was also well-tolerated, whilst being more convenient for patients. This short review assesses the role of this GnRH agonist in the treatment of prostate cancer...
  12. doi request reprint Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance
    Guillaume Ploussard
    Department of Urology, Pathology and Biochemistry, CHU Henri Mondor, APHP, Creteil, France
    Eur Urol 59:422-9. 2011
    ..The optimal selection of prostate cancer (PCa) patients for active surveillance (AS) is currently being debated...
  13. doi request reprint The contemporary concept of significant versus insignificant prostate cancer
    Guillaume Ploussard
    Department of Urology, Saint Louis Hospital, APHP, Paris, France
    Eur Urol 60:291-303. 2011
    ..The clinical relevance of such a definition was based on the fact that low-grade, small-volume, and organ-confined prostate cancer (PCa) may be indolent and unlikely to progress to biologic significance in the absence of treatment...
  14. doi request reprint The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance
    Guillaume Ploussard
    INSERM U955 Eq07 Department of Urology, APHP, CHU Henri Mondor, Creteil, France
    Eur Urol 61:356-62. 2012
    ..The impact of body mass index (BMI) on the risk of reclassification and deferred treatment in active surveillance (AS) programs has not been thoroughly assessed...
  15. ncbi request reprint Local recurrence after nephron-sparing surgery in von Hippel-Lindau disease
    Guillaume Ploussard
    Department of Urology, APHP, Bicetre Hospital, University of Paris Sud, Le Kremlin Bicetre, France
    Urology 70:435-9. 2007
    ..To evaluate the risks of local recurrence and repeat surgery after nephron-sparing surgery (NSS) in von Hippel-Lindau (VHL) disease to propose a therapeutic strategy to patients...
  16. pmc Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy
    Guillaume Ploussard
    INSERM, Unité 955 Université Paris Est, Faculté de Médecine AP HP, Groupe Henri Mondor Albert Chenevier, Service d Urologie, Département de Pathologie et Centre d Investigations Biomédicales, Creteil, France
    Cancer Res 70:9253-64. 2010
    ..Our findings suggest a role for βIII-tubulin as candidate theranostic biomarker to predict the response to docetaxel-based chemotherapy as well as to target for treatment of docetaxel-resistant CRPC...
  17. doi request reprint [Renal oncocytosis: case report]
    G Ploussard
    Service d Urologie, Universite Paris Sud, CHU le Kremlin Bicetre, AP HP, 78, rue Général Leclerc, 94275 Le Kremlin Bicetre, France
    Prog Urol 19:142-4. 2009
    ..These forms are most often sporadic or are integrated in the Birt-Hogg-Dube syndrome. We report here the case of a patient suffering from renal oncocytosis responsible for a diffuse renal involvement by numerous oncocytic nodules...
  18. pmc High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance
    Guillaume Ploussard
    Department of Urology APHP, INSERM U955 Eq07, CHU Henri Mondor, 94000 Creteil, France
    World J Urol 27:587-92. 2009
    ....
  19. doi request reprint [Pathological findings after radical prostatectomy in men eligible for active surveillance (French trial SURACAP): is the misclassification rate acceptable?]
    E Xylinas
    Service d Urologie, INSERM Unit 955 EQ7, Hopital Henri Mondor, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Prog Urol 21:264-9. 2011
    ..To analyze pathological data of the radical prostatectomy specimen in patients operated for clinically-localized prostate cancer and who meet strict criteria for active surveillance necessary to be included in the French trial SURACAP...
  20. pmc Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life
    G Ploussard
    INSERM U955 Eq07 Department of Urology, APHP, CHU Henri Mondor, Creteil, France
    Prostate Cancer Prostatic Dis 13:97-101. 2010
    ..This adjuvant combined therapy does not alter quality-of-life and continence recovery after surgery plus ADT. A larger cohort is awaited to determine the oncological outcomes of this strategy...
  21. doi request reprint [CCAFU Recommendations 2013: Prostate cancer]
    L Salomon
    Membre de la SFRO
    Prog Urol 23:S69-101. 2013
    ..The sub Comittee prostate of the CCAFU established guidelines for diagnostic, treatment, evaluation and standart of care of prostate cancer...
  22. doi request reprint [Prostate brachytherapy: indications and outcomes]
    C Hennequin
    Service de cancérologie radiothérapie, Hopital Saint Louis, AP HP, 1, avenue Claude Vellefeaux, 75475 Paris, France
    Prog Urol 23:378-85. 2013
    ..To summarize the indications and outcomes of low dose-rate prostate brachytherapy with permanent implants...
  23. doi request reprint [What is the importance of kidney cancer surgery in contrast with targeted therapies?]
    G Ploussard
    CHU Henri Mondor, AP HP, Service d Urologie, INSERM U955 Eq07, Université Paris XII Val de Marne, 51, Avenue du Marechal de Lattre de Tassigny, Creteil, France
    Bull Cancer 97:91-6. 2010
    ....
  24. doi request reprint [Laparoscopic radical prostatectomy in the elderly (>75 years old): oncological and functional results]
    E Xylinas
    Service d Urologie, Hopital Henri Mondor, AP HP, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Prog Urol 20:116-20. 2010
    ..Prostate cancer incidence increases with age. Radical prostatectomy (RP) seems to be feasible for elderly well-selected patients. We report our experience with patients older than 75 years old who underwent laparoscopic RP...
  25. pmc Increased expression of class III beta-tubulin in castration-resistant human prostate cancer
    S Terry
    INSERM, Unité 955, Créteil F 94000, France
    Br J Cancer 101:951-6. 2009
    ..Overexpression of betaIII-tubulin in these tumours is associated with an unfavourable outcome and resistance to taxane-based therapies. At present, betaIII-tubulin expression remains largely uncharacterised in prostate cancer...
  26. doi request reprint [Urinary biomarkers in prostate cancer: an update]
    X Durand
    INSERM U955, GHU Mondor Chenevier, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Prog Urol 20:1184-91. 2010
    ..In the near future, these markers would probably be able to provide prognostic data to discriminate significant cancers, a major challenge for prostate cancer treatment...
  27. doi request reprint Extended biopsy protocol decreases prostate cancer incidence and risk of aggressive disease on repeated biopsies compared with initial standard procedure
    Guillaume Ploussard
    INSERM U588 Eq07 Departments of Urology and Pathology, APHP, CHU Henri Mondor, Creteil, France
    Urol Int 84:147-52. 2010
    ..To compare prostate cancer detection rates in repeated biopsy depending on the number of cores at initial biopsy...
  28. doi request reprint Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Guillaume Ploussard
    Departments of Urology and Pathology, CHU Henri Mondor, Creteil, France
    J Urol 183:539-44. 2010
    ..We compared the pathological findings and prostate specific antigen outcome after radical prostatectomy in men eligible for active surveillance according to 3 biopsy inclusion criteria...
  29. doi request reprint [5 alpha-reductase inhibitors and prostate cancer: a statement of the Committee of Cancerology of the French Association of Urology]
    P Eschwege
    Service d Urologie, CHU de Nancy, Avenue de Bourgogne, 54500 Vandœuvre lès Nancy, France
    Prog Urol 22:555-60. 2012
    ..Two randomised trials and negative conclusion of the FDA about inhibitors of 5 alpha-reductase in prevention of prostate cancer need a revision of the indications of these drugs...
  30. doi request reprint Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer
    Guillaume Ploussard
    Department of Urology, APHP, CHU Henri Mondor, INSERM U955 Eq07, Creteil, France
    BJU Int 106:86-90. 2010
    ..Therapy (case series) Level of Evidence 4...
  31. doi request reprint The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number
    Guillaume Ploussard
    INSERM U955 Eq07, Department of Urology, APHP, CHU Henri Mondor, Creteil, France
    BJU Int 106:1293-7. 2010
    ..To study the development of stage migration in prostate cancer after controlling for the number of biopsy cores...
  32. doi request reprint The prognostic significance of bladder neck invasion in prostate cancer: is microscopic involvement truly a T4 disease?
    Guillaume Ploussard
    Department of Urology, APHP, CHU Henri Mondor, Creteil, France
    BJU Int 105:776-81. 2010
    ..However, BNI remains strongly associated with adverse pathology and should be regarded as a factor that worsens the prognosis of the underlying tumour stage...
  33. doi request reprint Bladder neck involvement as pT4 disease in prostate cancer: implications for prognosis and patient surveillance
    Guillaume Ploussard
    Department of Urology, Hospital Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, Creteil, France
    Future Oncol 5:803-10. 2009
    ..However, BNI remains strongly associated with adverse pathology and should be regarded as a factor that worsens the prognosis of the underlying tumor stage...
  34. doi request reprint Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen
    Guillaume Ploussard
    Institut National en Santé et Recherche Médicale U955 EQ7, Department of Urology, Assistance Publique Hopitaux de Paris, Centre Hospitalier Universitaire Henri Mondor, Creteil, France
    J Urol 182:1342-9. 2009
    ....
  35. doi request reprint Evaluation of combined oncological and functional outcomes after radical prostatectomy: trifecta rate of achieving continence, potency and cancer control--a literature review
    Evanguelos Xylinas
    INSERM, Unit 955 EQ7, Department of Urology APHP, CHU Henri Mondor, Creteil, France
    Urology 76:1194-8. 2010
    ..The preoperative risk (D'Amico) predicted for quality of life outcomes and biochemical recurrence is an aggregate endpoint, the trifecta...
  36. doi request reprint Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures
    Alexandre Paul
    INSERM U955 EQ7, Departments of Urology and Pathology APHP, CHU Henri Mondor, Creteil, France
    Eur Urol 57:267-72. 2010
    ..Although the first laparoscopic radical prostatectomy was performed in 1997, few midterm oncologic data have been published for the extraperitoneal procedure...
  37. pmc Analysis of complications from 600 retroperitoneoscopic procedures of the upper urinary tract during the last 10 years
    Dimitri Liapis
    INSERM U841EQ07, Department of Urology, CHU Mondor, 94000, Creteil, France
    World J Urol 26:523-30. 2008
    ..The aim of this study is to review 10 years experience of retroperitoneoscopy procedures...
  38. ncbi request reprint [To study the safety and effectiveness of heminephroureterectomy by horizontal lumbar posterior approach for duplicated systems in infants]
    Guillaume Ploussard
    Service de chirurgie pédiatrique viscérale, Service de Medecine Nucleaire, Hopital d Enfants Armand Trousseau, Paris, France
    Prog Urol 17:992-5. 2007
    ..To study the safety and effectiveness of heminephroureterectomy by horizontal lumbar posterior approach for duplicated systems in infants...